Heart FailureJECICANCT02892227
Management of Acute Heart Failure: Contribution of Ultrasound Daily "in Bed Patient" Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days
A study testing Transmitral flow estimation in people with Heart Failure, run by Centre Hospitalier Universitaire de Nīmes at 2 sites in France.
Trial summary
Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more… Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Heart Failure
- What is being tested?
- Transmitral flow estimation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 250 participants
- Where
- 2 sitesFrance
- Study dates
- 15 Nov 2016to 5 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The patient or his representative must be given free and informed consent and signed consent.
- The patient must be affiliated or beneficiary of a health insurance plan.
- The patient is available for a follow-up 6 months.
- The patient is of age or older (>) 18.
- Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV.
- Patient with impaired LVEF <50%.
- Patient with Nt-proBNP values> 1200pg / ml.
Who cannot join
- The subject takes part in another study.
- The subject is exclusion period determined by a previous study.
- The subject is under judicial protection.
- The subject or his representative refuses to sign the consent.
- It is not possible to give the subject or his representative informed information.
- Non-inclusion criteria for those diseases or conditions associated (s) interfere (s):
Show all 16Show fewer
- The patient is pregnant or is breastfeeding.
- The patient is already included in a surveillance program (PRADO, OSICAT).
- Patient with a mechanical or biological mitral prosthesis.
- History of mitral stenosis.
- severe valvular surgery with maturity in months (<30 days).
- chronic renal impairment on dialysis.
- High grade AV block (AVB and BAV3 2/1).
- Hypertrophic cardiomyopathy.
- Cardiogenic shock.
- Contraindications to furosemide.
Trial locations and contacts
2 sites in 1 country.
France2 sites
CHU Arnaud de Villeneuve
Montpellier, 34295
CHU Nimes
Nîmes, 30029
About this study
Official title: MANAGEMENT OF ACUTE HEART FAILURE: THE CONTRIBUTION OF DAILY 'BEDSIDE' ULTRASOUND TO THERAPEUTIC ADJUSTMENTS, WITH MEASURED IMPACT ON 30-DAY RE-HOSPITALISATION RATES
Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable.
This therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.
- Conditions
- Heart Failure
- Being tested
- Transmitral flow estimation
- Keywords
- bedside echography
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Transmitral flow estimationProcedure or surgery
Estimation of the transmitral flow of the inferior vena cava and its variations
| Study group | Role | What they receive |
|---|---|---|
| JET ECHO | Experimental | Transmitral flow estimation Receives: Procedure: Transmitral flow estimation |
| NO JET ECHO | No intervention | no bedside echocardiography |
What is being measured
The primary outcome is the main question the study is designed to answer.
rehospitalization
Measured: 30 days
Secondary outcomes (4)
mortality
Measured: 6 months
worsening heart failure
Measured: during hospitalization
average length of stay
Measured: during hospitalization
alteration of biological parameters myocardial, kidney and liver
Measured: Hospital discharge +7 days, Hospital discharge +30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2016 (estimated)
- Study start15 Nov 2016
- Primary completion5 Jun 2019
- Study completion5 Jun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NīmesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02892227
- Sponsor's protocol ID
- AOI/2015/JER-01
- Other IDs
- 2016-A00635-46
- Acronym
- JECICA
- Status last verified
- Dec 2018
- First submitted
- 26 Aug 2016
- Last updated
- 12 Mar 2026
- Results posted
- No
Publications
Ricci JE, Aguilhon S, Occean BV, Soullier C, Solecki K, Robert C, Huet F, Cornillet L, Schmutz L, Chevallier T, Akodad M, Leclercq F, Cayla G, Lattuca B, Roubille F. Impact of Daily Bedside Echocardiographic Assessment on Readmissions in Acute Heart Failure: A Randomized Clinical Trial. J Clin Med. 2022 Apr 6;11(7):2047. doi: 10.3390/jcm11072047.
PubMed 35407655
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MANAGEMENT OF ACUTE HEART FAILURE: THE CONTRIBUTION OF DAILY 'BEDSIDE' ULTRASOUND TO THERAPEUTIC ADJUSTMENTS, WITH MEASURED IMPACT ON 30-DAY RE-HOSPITALISATION RATES
- ClinicalTrials.gov ID
- NCT02892227
- Acronym / sponsor ID
- JECICA / AOI/2015/JER-01
- Conditions
- Heart Failure
- Keywords
- bedside echography
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NīmesUniversity, hospital or other
- Study start
- 15 Nov 2016 (actual)
- Primary completion
- 5 Jun 2019 (actual)
- Study completion
- 5 Jun 2019 (actual)
- First posted
- 8 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and reproducible estimation of filling pressures with an evaluation of mitral inflow and the inferior vena cava, allow a more reliable estimate of the true blood volume of the patient and thus lead to a therapeutic adjustment more suitable.
This therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30 days and mortality, less alteration of biological parameters myocardial, kidney and liver.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JET ECHO | Experimental | Procedure: Transmitral flow estimationTransmitral flow estimation |
| NO JET ECHO | No intervention | –no bedside echocardiography |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- The patient or his representative must be given free and informed consent and signed consent.
- The patient must be affiliated or beneficiary of a health insurance plan.
- The patient is available for a follow-up 6 months.
- The patient is of age or older (>) 18.
- Patients hospitalized for acute heart failure who received at least 40mg of furosemide IV.
Key exclusion criteria (16 listed)
- The subject takes part in another study.
- The patient is pregnant or is breastfeeding.
- The patient is already included in a surveillance program (PRADO, OSICAT).
- Patient with a mechanical or biological mitral prosthesis.
- History of mitral stenosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Transmitral flow estimationEstimation of the transmitral flow of the inferior vena cava and its variations | Procedure or surgery | JET ECHO |
Primary outcome
rehospitalization
Time frame: 30 days
4 secondary outcomes
mortality
Time frame: 6 months
worsening heart failure
Time frame: during hospitalization
average length of stay
Time frame: during hospitalization
alteration of biological parameters myocardial, kidney and liver
Time frame: Hospital discharge +7 days, Hospital discharge +30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Results publication: PubMed 35407655Ricci JE, Aguilhon S, Occean BV, Soullier C, Solecki K, Robert C, Huet F, Cornillet L, Schmutz L, Chevallier T, Akodad M, Leclercq F, Cayla G, Lattuca B, Roubille F. Impact of Daily Bedside Echocardiographic Assessment on Readmissions in Acute Heart Failure: A Randomized Clinical Trial. J Clin Med. 2022 Apr 6;11(7):2047. doi: 10.3390/jcm11072047.
Related trials for Heart Failure
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Recruiting
Evaluation of a French Hospital Discharge Therapeutic Education Program by Nurses for Heart Failure Patient (EduSor)
Heart Failure
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Not yet recruiting
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Transmitral flow estimation in people with Heart Failure, run by Centre Hospitalier Universitaire de Nīmes at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
rehospitalization (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02892227, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.